Latest News for: psma

Edit

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager ...

The Daily Sentinel 24 Feb 2026
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - ... .
Edit

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Pharmiweb 24 Feb 2026
Reductions on PSMA‑PET (positron emission tomography) affirm PSA declines and radiographic responses, with tumor shrinkage observed across multiple lesions, including visceral metastases.
Edit

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 ...

The Galveston Daily News 23 Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Feb 23, 2026-- ....
Edit

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer

PR Newswire 23 Feb 2026
VIR) today announced they have entered into a global strategic collaboration to advance VIR-5500, an investigational PRO-XTEN® dual-masked CD3 T-cell engager (TCE) targeting PSMA for the treatment of prostate cancer.
Edit

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer (Form 8-K) (Vir Biotechnology Inc)

Public Technologies 23 Feb 2026
) Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer.
Edit

SECuRE trial update: Another participant with undetectable PSA & negative PSMA PET

PR Newswire 23 Feb 2026
Undetectable disease by PSA was achieved after the first cycle, followed by a negative PSMA PET after the second cycle of 67Cu-SAR-bisPSMA ... PSMA PET ... Co-PSMA ... Ga-68 PSMA-11 in head-to-head trial.
Edit

PSMA-Targeted Therapy & Radiodiagnostics Competitor Analysis Report 2026: PYLARIFY Exceeds US$ 1 Billion in Net ...

Nasdaq Globe Newswire 20 Feb 2026
The main market opportunities lie in the commercialization and development of PSMA-targeted therapies and ...
Edit

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

PR Newswire 16 Feb 2026
HIGHLIGHTS Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released ... 0.48 for 68Ga-PSMA-11, with a difference of 0.78 (95% confidence interval [CI] ... Co-PSMA trial achieves primary endpoint.
Edit

Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for ...

Nasdaq Globe Newswire 04 Feb 2026
and PDRadiopharma Inc., the first patient has been dosed in the ...
Edit

NUCLIDIUM Announces Issuance of New U.S. Patent Covering its 61Cu-based Radiodiagnostic Program for PSMA-positive Prostate Cancer

Nasdaq Globe Newswire 26 Jan 2026
Patent for composition of matter & methods of use of high-radiopure diagnostic ⁶¹Cu-NU101 & combination use w/ 67Cu- therapeutic in PSMA+ prostate cancer ... .
Edit

PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight

PR Newswire 20 Jan 2026
Learn more about the PSMA-targeted therapy @ PSMA-targeted Therapy Analysis ... The therapy targets PSMA by pairing a PSMA-selective ligand, PSMA-I&T, with no-carrier-added lutetium-177, a beta-emitting radioisotope ... Key PSMA-targeted Therapies.
Edit

Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026

The Facts 24 Dec 2025
SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX.
Edit

PSMA scheme saved 13k high-risk pregnant women in Mysuru district

The Times of India 13 Dec 2025
+Text SizeSmallMediumLarge. .
Edit

PSMA-Targeted Therapy & Radiodiagnostics Competitor Analysis Report 2025 - ResearchAndMarkets.com

Business Wire 02 Dec 2025
PSMA-Targeted Therapy & Radiodiagnostics" report has been added to ResearchAndMarkets.com's offering.
Edit

Summary report on authorisation – 18F-PSMA-1007 ZRP® (Swissmedic - Swiss Agency for Therapeutic Products)

Public Technologies 21 Nov 2025
11 June 2024 Solution for injection for the detection by imaging of PSMA-positive lesions in adults with prostate cancer About the medicinal product ...

Article Search

tools
×
×
×
×